The Company is pleased to announce that Mr Swen-Henrik Grundmann has been appointed as a non-executive Director of Reinet Investments Manager S.A., with effect as of 18 November 2024. Reinet ...
“The initiation of the GTA182 Phase 1a/b clinical trial represents a significant milestone in our company’s growth and marks our second drug candidate to enter clinical studies,” said Mingxi Li, Ph.D.